|Dr. Graeme Leslie Blackman OAM, BSc (Hons), Ph.D., FRACI, FTSE||Founder and Advisor||48.58k||N/A||72|
|Ms. Joanna Johnson BEc, ICAA||CFO & Joint Company Sec.||257.89k||N/A||N/A|
|Dr. David Sparling BVSc (Hons), LLB (Hons), GDipAppCGov||VP of Corp. & Bus. Devel. and Joint Sec.||311.92k||N/A||N/A|
|Mr. Graeme R. Kaufman BSc, MBA||Exec. Director||98.4k||N/A||69|
|Ms. Mary E. Sontrop BAppSc,GDip Hel.Adm, GDip. QM, MBA||Exec. Officer & Exec. Director||23.33k||N/A||61|
IDT Australia Limited engages in the development and commercial manufacture of active pharmaceutical ingredients (API) and finished drug products worldwide. The company offers research and development, validation, and testing services for API, including cytotoxics, anti-cancer drugs, antibiotics, beta lactams, and controlled drugs, as well as generic medicines into finished dosage forms. Its services also include laboratory, functional support, project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs. The company is headquartered in Boronia, Australia.
IDT Australia Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.